The Emerging Role of Gut Microbiota in Metabolic Diseases

The human gut microbiota, consisting of around 100 trillion microorganisms, plays an essential role in regulating metabolic balance and supporting overall health. It is well documented that dysbiosis is associated with a number of metabolic disorders including type 2 diabetes mellitus (T2DM), obesity, hypercholesterolemia, and cardiovascular diseases (CVDs). Recent studies have shown that the gut microbiome influences metabolism, immune responses, and even neuroendocrine signaling by producing metabolites like short-chain fatty acids. In obesity, the altered Firmicutes/Bacteroidetes ratio is linked to increased energy harvest from the diet. At the same time, specific bacterial taxa such as Akkermansia muciniphila and Faecalibacterium prausnitzii exhibit anti-inflammatory properties and are inversely correlated with obesity-related inflammation. Dysbiosis in T2DM is associated with reduced levels of beneficial bacteria like Bifidobacterium and Roseburia, which are important for maintaining gut barrier integrity and regulating immune responses. Furthermore, hypercholesterolemia and CVDs have also been linked to gut microbiota composition. Specific bacterial strains, including Lactobacillus and Clostridium, are involved in bile acid metabolism, cholesterol homeostasis, and the modulation of lipid levels. This review article aims to provide an in-depth analysis of the role of gut microbiota in metabolic diseases, exploring the underlying mechanisms of microbial dysbiosis and its contribution to disease progression. Targeting microbial dysbiosis through therapeutic interventions such as probiotics, prebiotics, and dietary modifications could offer promising strategies for preventing and managing metabolic disorders, thereby improving overall health outcomes.